Last reviewed · How we verify

NCT05140434: DP-Cor-1

Evaluation of the Benefit of Exercise Testing for the Diagnosis of Obstruction in the Coronary Arteries of the Heart

Recruiting now Last updated 14 March 2025
What this trial tests

trial testing Exercise test in Coronary Artery Disease in 120 participants. Currently enrolling.

Timeline
4 May 2022
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorCentre Hospitalier Sud Francilien
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment120
Start date4 May 2022
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Sud Francilien

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether exercise testing can detect an obstruction in a coronary artery, and, thereby, can avoid performing a coronary imaging in some cases. Patients with a suspicion of coronary artery disease perform an exercise test on an exercise bike with increasing load. EKG, blood pressure, and other parameters are monitored. Patients benefit also of either a cardiac CT scan or a coronary angiography to establish whether they really have coronary obstruction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Exercise test

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Centre Hospitalier Sud Francilien trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05140434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing